TopGum acquires PharmItBe to fortify its supply chain and accelerate development of pharma-grade gummy supplements

Evgenia Lozinsky, PhD, the company’s former CEO as TopGum’s vice president of research and development. Photo credit: Mishel Amzallag (he, him)

TopGum Industries Ltd. (Tel Aviv, Israel) has signed an agreement to purchase PharmItBe Ltd., naming Evgenia Lozinsky, PhD, the company’s former CEO as TopGum’s vice president of research and development. Through this acquisition, TopGum will have full access to PharmItBe’s fully equipped FDA certified laboratory and its comprehensive analytical services, ensuring strict quality standards even while condensing lead times for the supply chain process. The addition of PharmItBe’s R&D capabilities will also accelerate TopGum’s pharma-grade gummy development of a new facility. The plant, supported by a $40 million investment, is scheduled to be operational by the of 2023.

Lozinsky founded PharmItBe in 2016 as an advanced analytical laboratory that develops formulations and new delivery formats, as well as providing analytical services to international pharmaceutical, dietary supplement, and food companies. As vice president of R&D at TopGum, Lozinsky will oversee all the company’s R&D activities, including the innovation of new products for customers, developing a unique microencapsulation formula, creating products for the new TopGum facility, and leading the development of pharma-grade OTC gummies.

PharmItBe will continue to operate as a stand-alone, FDA-certified analytical lab as TopGum’s future subsidiary and provide services to other leading international companies. Lozinsky will serve as president of PharmItBe as well.

“It is exciting to have PharmItBe join the TopGum family,” said Amichai Bar-Nir, TopGum CEO, in a press release. “I look forward to our developing the next generation of gummy supplements. This acquisition makes it possible to improve our supply-chain process and meet the highest quality standards internationally, which will allow us to provide better service to our customers worldwide. Our ability to deliver on innovation, quality, and service should be greatly enhanced.”

“We are proud to report this important milestone for the company's expansion,” added Hagai Stadler, chairman of TopGum. “The acquisition will allow TopGum to accelerate the development of products for the pharmaceutical world, as well as improve the company’s supply chain, quality assurance, and operational efficiencies. We are happy to have Dr. Lozinsky as part of TopGum’s management team.”

“I am eager to lead TopGum’s R&D and channel our mutual experience to bringing the company to new heights,” professed Lozinsky. “PharmItBe found the perfect ‘family’ to continue its journey, and as an experienced formulation and chemistry analytical developer, I look forward to working closely with TopGum’s management team to further the company’s vision and success.”